Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
<!-- Name:DistributionId Value:8788196 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Browsing Tag
BPX-603
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at…